This is the classic website, which will be retired eventually. Please visit the modernized instead.

Key Record Dates Identifier: NCT05111626
Brief Title: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

First Submitted : October 29, 2021
First Submitted that Met QC Criteria : October 29, 2021
First Posted : November 8, 2021

Last Update Submitted that Met QC Criteria : March 27, 2024
Last Update Posted : March 28, 2024